Shareholders approve all other proposals by the Board of Directors, including the reduction of share capital, the 2025 report on nonfinancial matters and the 2025 Compensation Report, as well as the ...
CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4 ...
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
Phase III program in food allergy (FA) planned for H2 2026 ...
Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients East Hanover, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global ...
Annual Report 2025 and US Securities & Exchange Commission Form 20-F 2025 These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030 Marks latest milestone in company’s previously announced $23 billion ...
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of ...
. *Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results